AQA
NKTR icon

Alpha Quant Advisors’s Nektar Therapeutics NKTR Stock Holding History

Alpha Quant Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$241K Sell
477
-322
-40% -$191K 0.24% 111
2018
Q4 		$394K Buy
+799
New +$482K 0.41% 85

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alpha Quant Advisors's NKTR Position: Q1 2019 in Review

Alpha Quant Advisors reduced its Nektar Therapeutics (NKTR) stake by 40% in Q1 2019, selling an estimated $191K and leaving 477 shares worth $241K. The position accounts for 0.24% of the portfolio, ranked #111.

Alpha Quant Advisors first reported a position in NKTR in Q4 2018 and has held it in 2 quarters since. The position peaked at $394K in Q4 2018. 349 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Alpha Quant Advisors held 477 shares of Nektar Therapeutics worth $241K as of Q1 2019.
  • Alpha Quant Advisors sold 322 Nektar Therapeutics shares in Q1 2019, an estimated $191K.
  • Nektar Therapeutics made up 0.24% of Alpha Quant Advisors's portfolio in Q1 2019, its #111 holding.
  • Alpha Quant Advisors first reported a position in Nektar Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • Alpha Quant Advisors's Nektar Therapeutics position peaked at $394K in Q4 2018.
  • 349 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Alpha Quant Advisors's 13F filing for Q1 2019, filed 8 May 2019.